Man, if CYDY only went to .55 on a licensing deal for HIV that had upfront cash, I just might quit! Heck, even a licensing deal for the prostate test should move the SP as upfront cash and future revenues are what CYDY needs.

Personally, the first patient injected in the TNBC trial would be nice. I’m very interested to see how well leronlimab works in cancer patients as that would be a game changer for patients and for investors.